Crestor Muscle Risk No Greater Than Other Statins, FDA Says; Death Reported
Executive Summary
FDA's current view is that there is no greater risk for muscle injury with AstraZeneca's cholesterol lowering drug Crestor than with other statins, the agency said
You may also be interested in...
Crestor DTC Ads To Resume Following Safety Labeling Update
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose
Crestor DTC Ads To Resume Following Safety Labeling Update
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose
ClinicalTrials.gov Postings Should Include Studies For All Diseases – PhRMA
PhRMA member companies are committing to posting clinical study information on the ClinicalTrials.gov database for all diseases and conditions, not only for those that are "serious or life-threatening.